You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise

New data presented at the European Hematology Association 2021 (EHA) virtual congress shows patients treated with Vertex/CRISPR Therapeutics’ blood disorder gene therapy CTX001 had ‘sustained response[s]’ to treatment’.